- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06283251
PediRISE Feasibility
Pilot Randomized Pediatric RISE (Resource Intervention to Support Equity) Feasibility Study
The goal of this research study is to learn whether investigators can successfully give the PediRISE program to families-in other words, whether most families are interested in participating in a study about the PediRISE program, including a 50-50 chance of receiving standard usual care, and a 50-50 chance of receiving the PediRISE support program.
The names of the study groups in this research study are:
- PediRISE Program Group
- Usual Care Group
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a pilot, multi-center, randomized research study for the feasibility of the administration of the PediRISE program among 40 poverty exposed children with newly diagnosed cancer. Randomization means there is an equal chance of being assigned to the PediRISE Program Group or the Usual Care Group.
Study procedures include screening for eligibility, study visits, and completion of surveys and questionnaires.
Participation in this study will last for about 6-months.
It is expected that about 40 pediatric participants with parents/guardians will take part in this research study.
This study is being supported by grants from the American Cancer Society and the Children's Cancer Research Fund.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kira Bona, MD, MPH
- Phone Number: 617-632-4688
- Email: Kira_Bona@dfci.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
Contact:
- Kira Bona, MD, MPH
- Phone Number: 617-632-4688
- Email: Kira_Bona@dfci.harvard.edu
-
Principal Investigator:
- Kira Bona, MD, MPH
-
Boston, Massachusetts, United States, 02215
- Boston Children's Hospital
-
Contact:
- Kira Bona, MD, MPH
- Phone Number: 617-632-4688
- Email: Kira_Bona@dfci.harvard.edu
-
Principal Investigator:
- Kira Bona, MD, MPH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Child diagnosed with de novo cancer
- Child has established care at a study site and initiated cancer-directed therapy in the prior 2-months
- Child planned to receive at least 4-months of cancer-directed therapy at study site from time of diagnosis per initial cancer treatment plan
- Child is <18 years at time of enrollment
- Parent/guardian screened positive for self-reported low-income (<200% FPL).
- Family primary residence in MA, NY or NJ
- Provider approval for permission to approach
Exclusion Criteria:
- Planned transfer of child to a non-DFCI or non-Columbia facility for cancer-directed therapy
- Foreign national family receiving care as an Embassy-pay patient
- Child is enrolled on embedded correlative health equity aims of open or upcoming clinical drug trials which are powered on descriptive parent-reported poverty data (e.g. AALL1731, AHOD2131, ANBL2131, DFCI 23-001).
- Child or household member receiving SSI.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PediRISE Program Group
Participants will be randomized in a 1:1 fashion and will be stratified by site. Participant parents will complete:
|
A centrally administered, income-poverty targeted intervention that includes twice-monthly direct provision of unrestricted cash transfers along with benefits counseling to mitigate the risk of loss of means-tested benefits.
Funds will be dispersed to families via provided debit card or through personal banking, PayPal, or Venmo.
Other Names:
|
No Intervention: Usual Care Group
Participants will be randomized in a 1:1 fashion and will be stratified by site. Participant parents will complete:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Participant Consent
Time Frame: 1 Day
|
Feasibility of intervention is defined as >75% of screened participants consent to randomization.
|
1 Day
|
6-Month Follow Up Rate for PediRISE Program Group
Time Frame: At 6 months
|
Feasibility of the intervention is defined as <20% of randomized participants who do not complete 6-month survey in PediRiSE Program group.
|
At 6 months
|
6-Month Follow Up Rate for Usual Care Group
Time Frame: At 6 months
|
Feasibility of the intervention is defined as <20% of randomized participants who do not complete 6-month survey in Usual Care Group.
|
At 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kira Bona, MD, MPH, Dana-Farber Cancer Institute
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-590
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Cancer
-
Emory UniversityNational Cancer Institute (NCI)Recruiting
-
Ann & Robert H Lurie Children's Hospital of ChicagoSilicon Valley Community FoundationUnknownCancer | Pediatric CancerUnited States
-
University of BirminghamCompletedCancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AMLUnited Kingdom, Australia, Netherlands
-
Alexandria UniversityCompletedPediatric Cancer | Invasive CancerEgypt
-
University of California, San DiegoNational Cancer Institute (NCI); Dana-Farber Cancer Institute; University of... and other collaboratorsNot yet recruiting
-
Immune Oncology Research InstituteRecruitingContinuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With DexamethasonePediatric CancerArmenia
-
Connecticut Children's Medical CenterThe Hospital for Sick ChildrenRecruitingPediatric CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingPediatric CancerUnited States
-
Erin RowellRecruiting
-
Giselle ShollerRecruiting
Clinical Trials on PediRISE Resource Program
-
University of ReginaProvincial Health Services Authority; Saskatchewan Health Authority - Regina...Not yet recruitingMental Health | Cystic Fibrosis in Children | Siblings | Internet-based InterventionCanada
-
University of ReginaProvincial Health Services Authority; Saskatchewan Health Authority - Regina...RecruitingCystic Fibrosis | Mental Health | Siblings | Internet-based InterventionCanada
-
Workit HealthUnknownAlcohol Use Disorder | Addictive Behavior | Drug Abuse | Alcohol Abuse | Drug Use DisordersUnited States
-
University GhentFund for Scientific Research, Flanders, Belgium; International Centre for Reproductive...CompletedIntimate Partner ViolenceBelgium
-
University of BernRecruitingSuicide, Attempted | Self Efficacy | Suicide Ideation | Locus of Control | Inhibitory Control | Process Factors | Movement SynchronySwitzerland
-
University of HohenheimCompleted
-
Brigham and Women's HospitalBristol-Myers SquibbRecruitingRheumatoid Arthritis | Systemic Sclerosis | Inflammatory Arthritis | Psoriatic Arthritis | Sjogren's Syndrome | Juvenile Rheumatoid Arthritis | Ankylosing Spondylitis | Undifferentiated Connective Tissue Diseases | Lupus | Sacroiliitis | Sicca Syndrome | Mixed Connective Tissue Disease | Palindromic Arthritis | Enteropathic...United States
-
Boston Medical CenterNational Institute of Mental Health (NIMH)Active, not recruitingAttention Deficit/Hyperactivity Disorder | InattentionUnited States
-
Wake Forest University Health SciencesNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingHypertensionUnited States